Lanthanum carbonate
Alternative Names: Bay 771931; Fosrenol; Foznol; Lambda; SPD405Latest Information Update: 05 Nov 2023
At a glance
- Originator Genzyme Corporation
- Developer Bayer Yakuhin; Shire; Takeda
- Class Hyperphosphataemia therapies; Lanthanoid series elements; Small molecules
- Mechanism of Action Phosphate binding modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Hyperphosphataemia
Most Recent Events
- 11 Jun 2021 Launched for Hyperphosphataemia in Czech Republic, Japan, Austria, Belgium, France, Germany, Portugal, China, Sweden, Greece, Norway, Denmark, Hungary, Poland (PO)
- 08 Jan 2019 Shire has been acquired and merged into Takeda
- 16 Nov 2018 Shire completes a phase II trial in Hyperphosphatemiain Argentina, Chile, Czech Republic, Germany, Hungary, Poland, Romania, Russia and Turkey (NCT01696279)